Global CAR-T cell therapy market stood at USD1709.00 million in 2021 and is expected to grow at a CAGR of 64.66% during the forecast period. This can be attributed to the increasing prevalence of different types of cancer globally. Additionally, the approval of new CAR-T cell therapies such as ABECMA (idecabtagene vicleucel) increased the demand for CAR-T cell therapies for the treatment of cancer. This, in turn, fueled the market growth of CAR-T cell therapy globally. Additionally, the increase in the number of cell therapy clinical studies, especially in the United States and China, also supports market growth over the next few years. Also, flourishing pharmaceutical research expenditure by both the governments and private industries across the different regions is expected to foster market growth during the forecast period.

Focus on Personalized Medicine Driving Market Growth

Personalized medicine is the beginning to overcome all the limitations of traditional medicine. Increasing personalized medicines allows healthcare providers to shift the emphasis in medicine from reaction to prevention. Personalized medicines have the potential to improve health care while also lowering costs. It enables an earlier diagnosis, risk management, and better treatment for the patient. Growing public knowledge and acceptance of customized medicine has fueled demand for cell-based therapies like CAR-T cell therapy to treat a variety of chronic illnesses.

Growing Prevalence of Cancer Supporting Market Growth

During the projected period, the rising prevalence of various types of cancer, particularly various forms of Lymphoma and Leukemia, is expected to boost the growth of the global CAR-T cell therapy market. According to Globocan statistics, there were roughly 19,292,789 new cancer cases registered in 2020. Breast, lung, colorectum, prostate, and stomach cancer were the most common kinds of cancer. Similarly, Non-Hodgkin Lymphoma was rated 12th, while Leukemia was placed 14th, with 544,352 and 474,519 instances reported for each kind, respectively. CAR-T cell therapies are used to treat different types of cancer which supports the market growth. For instance, YESCARTA is a CAR-T cell therapy, which is used to treat large B-cell lymphoma or follicular lymphoma.

Increase in Cell Therapy Clinical Studies Aids Market Growth

The growing awareness related to cell-based therapies and their benefits in treating various types of diseases and disorders has increased the research & development activities related to cell-based therapies, which leads to an increase in the number of clinical trials worldwide. Additionally, many people are eager to get themselves enrolled in clinical studies especially related to CAR-T cell therapy, thereby fueling the market growth through 2027. For instance, 1304 ongoing or upcoming CAR-related trials were registered at ClinicalTrials.gov as of December 22, 2020. Out of which, a total of 433 trials (56%) were from China and 288 (37%) from the United States.

Increasing Demand for Organic Pesticides to support Market Growth

Organic pesticide market growth is primarily driven by rising consumer awareness of organic products and foods. Synthetic pesticides used in agricultural production are detrimental to humans and the environment. Organic pesticides are chemical-free, environmentally beneficial, and create fewer toxic residues, making them essential for organic farming. The demand for organic pesticides is also influenced by increased disposable income, environmental concerns, and comparable prices.

Faster Approvals of CAR-T Cell Therapies Supports the Market Growth

The first CAR-T cell therapy was approved on August 30, 2017, by the brand name of Kymirah and the second was approved in the same year by the name of Yescarta. Till December 2021, there are five approved CAR-T cell therapies globally. The most recent approved CAR-T cell therapy is Abecma by Bluebird Bio and BMS and is approved in the year 2021. This number is continuously increasing as many CAR-T cell therapies are on the edge of approval by the US-FDA. For instance, in September 2021, China’s National Medical Products Administration (NMPA) has approved its CAR-T cell immunotherapy of JW Therapeutics’ Relmacabtagene autoleucel injection by the brand name of relma-cel.


Click here to download the sample

Market Segmentation

The global CAR-T cell therapy market is segmented based on product type, tumor type, indication, treatment type, targeted antigen, end user, company, and regional distribution. On the basis of product type, the market can be split into YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), TECARTUS (brexucabtagene autoleucel), BREYANZI (lisocabtagene maraleucel), ABECMA (idecabtagene Vicleucel), and Others. Based on tumor type, the market is divided into Hematological Malignancies and Solid Tumors.

Based on indication, the market can be divided into Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Others. In terms of treatment type, the market divided into Single Treatment and Combination Treatment. Based on targeted antigen, the market is segmented into CD 19, BCMA, and Others. In terms of end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others.

Company Profiles

Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc, and among others are among the major market players in the regional platform that lead the market growth of the Global CAR-T Cell therapy market.

Attribute

Details

Market size value in 2021

USD1709.00 Million

Revenue Forecast in 2027

USD33153.30 Million

United States Market Size in 2021

USD784.31 Million

Growth Rate

64.66%

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         Product Type

·         Tumor Type

·         Indication

·         Treatment type

·         Targeted Antigen

·         End User

Regional Scope

North America, Europe, Asia Pacific, South America, Middle East & Africa

Country Covered

United States, Canada, Mexico, Germany, France, Switzerland, United Kingdom, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Argentina, Colombia, Israel, South Africa, Saudi Arabia, UAE

Key Companies Profiled

Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request)

 

Report Scope:

In this report, Global CAR-T Cell Therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global CAR-T Cell Therapy, By Product Type:
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Tecartus (Brexucabtagene Autoleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Others
  • Global CAR-T Cell Therapy Market, By Tumor Type:
    • Hematological Malignancies
    • Solid Tumors
  • Global CAR-T Cell Therapy Market, By Indication:
    • Diffused Large B-Cell Lymphoma (DLBCL)
    • Acute Lymphoblastic Leukemia (ALL)
    • Follicular Lymphoma (FL)
    • Mantle Cell Lymphoma (MCL)
    • Others
  • Global CAR-T Cell Therapy Market, By Treatment Type:
    • Single Treatment
    • Combination Treatment
  • Global CAR-T Cell Therapy Market, By Targeted Antigen
    • CD19
    • BCMA
    • Others
  • Global CAR-T Cell Therapy Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Global CAR-T Cell Therapy Market, By Region:
    • North America
    • Europe
    • Asia-Pacific
    • South America
    • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.     Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on Global CAR-T Cell Therapy Market

5.    Voice of Customers

5.1.  Brand Awareness

5.2.  Unmet Need and Challenges

5.3.  Factors Driving the CAR-T Cell Therapy Market

6.    Global CAR-T Cell Therapy Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)

6.2.2.     By Tumor Type (Hematological Malignancies, Solid Tumors)

6.2.3.     By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

6.2.4.     By Treatment Type (Single Treatment, Combination Treatment)

6.2.5.     By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

6.2.6.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.7.     By Region  

6.2.8.     By Company

6.3.  Market Map

7.    North America CAR-T Cell Therapy Market Outlook, 2016-2026F

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Product Type

7.2.2.     By Tumor Type

7.2.3.     By Indication

7.2.4.     By Treatment Type

7.2.5.     By Targeted Antigen

7.2.6.     By End User

7.2.7.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States CAR-T Cell Therapy Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value 

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Product Type

7.3.1.2.2.             By Tumor Type

7.3.1.2.3.             By Indication

7.3.1.2.4.             By Treatment Type

7.3.1.2.5.             By Targeted Antigen

7.3.1.2.6.             By End User

7.3.2.     Canada CAR-T Cell Therapy Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value 

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Product Type

7.3.2.2.2.             By Tumor Type

7.3.2.2.3.             By Indication

7.3.2.2.4.             By Treatment Type

7.3.2.2.5.             By Targeted Antigen

7.3.2.2.6.             By End User

7.3.3.     Mexico CAR-T Cell Therapy Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value 

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Product Type

7.3.3.2.2.             By Tumor Type

7.3.3.2.3.             By Indication

7.3.3.2.4.             By Treatment Type

7.3.3.2.5.             By Targeted Antigen

7.3.3.2.6.             By End User

8.    Europe CAR-T Cell Therapy Market Outlook, 2016-2026F

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Product Type

8.2.2.     By Tumor Type

8.2.3.     By Indication

8.2.4.     By Treatment Type

8.2.5.     By Targeted Antigen

8.2.6.     By End User

8.2.7.     By Country

8.3.  Europe: Country Analysis

8.3.1.     Germany CAR-T Cell Therapy Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value 

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Product Type

8.3.1.2.2.             By Tumor Type

8.3.1.2.3.             By Indication

8.3.1.2.4.             By Treatment Type

8.3.1.2.5.             By Targeted Antigen

8.3.1.2.6.             By End User

8.3.2.     France CAR-T Cell Therapy Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value 

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Product Type

8.3.2.2.2.             By Tumor Type

8.3.2.2.3.             By Indication

8.3.2.2.4.             By Treatment Type

8.3.2.2.5.             By Targeted Antigen

8.3.2.2.6.             By End User

8.3.3.     Switzerland CAR-T Cell Therapy Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value 

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Product Type

8.3.3.2.2.             By Tumor Type

8.3.3.2.3.             By Indication

8.3.3.2.4.             By Treatment Type

8.3.3.2.5.             By Targeted Antigen

8.3.3.2.6.             By End User

8.3.4.     United Kingdom CAR-T Cell Therapy Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value 

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Product Type

8.3.4.2.2.             By Tumor Type

8.3.4.2.3.             By Indication

8.3.4.2.4.             By Treatment Type

8.3.4.2.5.             By Targeted Antigen

8.3.4.2.6.             By End User

8.3.5.     Italy CAR-T Cell Therapy Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value 

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Product Type

8.3.5.2.2.             By Tumor Type

8.3.5.2.3.             By Indication

8.3.5.2.4.             By Treatment Type

8.3.5.2.5.             By Targeted Antigen

8.3.5.2.6.             By End User

8.3.6.     Spain CAR-T Cell Therapy Market Outlook

8.3.6.1.         Market Size & Forecast

8.3.6.1.1.             By Value 

8.3.6.2.         Market Share & Forecast

8.3.6.2.1.             By Product Type

8.3.6.2.2.             By Tumor Type

8.3.6.2.3.             By Indication

8.3.6.2.4.             By Treatment Type

8.3.6.2.5.             By Targeted Antigen

8.3.6.2.6.             By End User

9.    Asia-Pacific CAR-T Cell Therapy Market Outlook, 2016-2026F

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Product Type

9.2.2.     By Tumor Type

9.2.3.     By Indication

9.2.4.     By Treatment Type

9.2.5.     By Targeted Antigen

9.2.6.     By End User

9.2.7.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China CAR-T Cell Therapy Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value 

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Product Type

9.3.1.2.2.             By Tumor Type

9.3.1.2.3.             By Indication

9.3.1.2.4.             By Treatment Type

9.3.1.2.5.             By Targeted Antigen

9.3.1.2.6.             By End User

9.3.2.     Japan CAR-T Cell Therapy Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value 

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Product Type

9.3.2.2.2.             By Tumor Type

9.3.2.2.3.             By Indication

9.3.2.2.4.             By Treatment Type

9.3.2.2.5.             By Targeted Antigen

9.3.2.2.6.             By End User

9.3.3.     India CAR-T Cell Therapy Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value 

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Product Type

9.3.3.2.2.             By Tumor Type

9.3.3.2.3.             By Indication

9.3.3.2.4.             By Treatment Type

9.3.3.2.5.             By Targeted Antigen

9.3.3.2.6.             By End User

9.3.4.     Australia Global CAR-T Cell Therapy Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value 

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Type